MarketFriction

Laurus Labs Ltd

NSE LAURUSLABS · BSE 540222 · Pharmaceuticals
₹1,984.00 +0.20%
NSE close2026-10-01
52 week range827.25 - 2,055.30
Market cap₹1,06,928 Cr.
P/E97.8
Nifty 200Nifty 500Nifty Midcap 50Nifty Midcap 100Midcap 150Nifty PharmaNifty Healthcare Index No price band Delivery 46.2%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,2241,1951,4401,1951,2241,4151,7201,5701,6531,7781,8122,026
Expenses1,0371,0141,1981,0241,0451,1301,3001,1871,2501,2981,2991,388
Operating Profit188181241171178285421382403480512638
OPM %15%15%17%14%15%20%24%24%24%27%28%32%
Other Income22193595910276129
Interest425150495358565240394042
Depreciation9398102106108106110117120121122124
Profit before tax54351071823131312224270327361481
Tax %27%27%30%34%22%31%25%28%28%22%22%25%
Net Profit372375132093233162194252282362
EPS in Rs0.690.431.400.230.371.714.333.023.614.665.176.80
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales1,7781,9052,0562,2922,8324,8144,9366,0415,0415,5546,8137,270
Expenses1,4151,4971,6421,9352,2663,2623,5124,4484,2614,4995,0285,236
Operating Profit3624084143575651,5521,4241,5927791,0551,7852,034
OPM %20%21%20%16%20%32%29%26%15%19%26%28%
Other Income432291552314624754754
Interest11110080889068102165183216171161
Depreciation86106125164187205251324385430480487
Profit before tax1692342371202941,3011,0841,1092364841,1821,439
Tax %21%19%29%22%13%24%23%28%29%27%25%
Net Profit134190168942559848327931623588901,091
EPS in Rs16.973.603.161.764.7718.3315.4014.672.986.6416.4620.24
Dividend Payout %2%8%9%17%10%11%13%14%27%18%12%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth14%7%4%23%
Compounded Profit Growth21%-2%4%115%
Stock Price CAGR%26%71%135%
Return on Equity17%15%10%18%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital1616106106106107107107108108108108
Reserves6407741,2251,3771,4521,6632,4903,2443,9304,0034,3655,192
Borrowings8881,0948429801,0361,0791,4821,7772,0152,5772,7642,518
Other Liabilities3453394815547379011,6711,8401,6081,6992,0992,693
Total Liabilities1,8882,2242,6533,0173,3313,7505,7516,9687,6608,3879,33610,511
Fixed Assets8011,0211,2301,4811,6291,7262,1712,6523,4093,8904,1234,371
CWIP1107014316311067362813551423458773
Investments77333333150124233309
Other Assets9701,1261,2771,3691,5891,9533,2143,4723,6513,9504,5215,058
Total Assets1,8882,2242,6533,0173,3313,7505,7516,9687,6608,3879,33610,511
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity-651823323422983477339119946666021,624
Cash from Investing Activity-397-312-289-384-253-221-941-914-997-822-680-1,086
Cash from Financing Activity486103-5442-45-12825530-2725039-525
Net Cash Flow24-27-101-0-14727-3093-3913
Free Cash Flow-447-14455-494412549346-1061560
CFO/OP-24%59%94%98%91%68%62%77%80%99%70%107%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days78911091011131029910096120132115
Inventory Days210176186201201234266293222277285317
Days Payable102909610714415919914694158141170
Cash Conversion Cycle186178199195170177166247224240276263
Working Capital Days-0193-11615434359424358
ROCE %14%16%16%14%8%14%40%26%23%7%9%18%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters27.20%27.18%27.18%27.18%27.18%27.62%27.62%27.60%27.60%27.49%27.49%27.47%
FIIs24.03%25.39%25.98%25.67%26.08%25.56%25.51%25.70%26.17%26.52%25.82%28.00%
DIIs11.01%11.13%11.78%13.56%13.05%12.74%11.78%11.94%11.72%12.42%13.96%13.73%
Public37.75%36.30%35.07%33.59%33.69%34.09%35.09%34.78%34.52%33.57%32.73%30.79%
No. of Shareholders4,02,6403,82,8803,56,8303,24,0593,09,0632,92,2142,92,9052,80,2232,83,6782,80,7562,92,2812,91,653

Fundamentals

Market Cap₹ 1,06,928 Cr.
Current Price₹ 1,979
Stock P/E97.8
Book Value₹ 98.2
ROCE17.8 %
ROE18.3 %
Dividend Yield0.10 %
Face Value₹ 2.00
Compounded Sales Growth (TTM)23%
Compounded Profit Growth (TTM)115%
Consolidated figures.
Valuation
Market capRs 107,108 Cr
Enterprise valueRs 109,512 Cr
P/E (TTM)97.96x
Price to book20.21x
Price to sales14.73x
EV / EBITDA52.46x
EV / EBIT68.43x
EV / sales15.06x
Price to cash flow65.97x
Earnings yield1.02%
Dividend yield0.10%
P/E, 3-year average94.77x
P/B, 3-year average7.55x
P/E, 5-year average68.52x
P/B, 5-year average7.20x
Profitability
Operating margin (excl. other income)26.20%
Operating margin (incl. other income)26.90%
EBITDA margin28.72%
Pre-tax margin19.79%
Net profit margin15.04%
Net margin, latest quarter18.14%
ROE18.19%
ROCE17.97%
ROA8.96%
ROE, 3-year average10.16%
ROCE, 3-year average11.54%
ROA, 3-year average5.00%
ROE, 5-year average15.94%
ROCE, 5-year average16.63%
ROA, 5-year average7.76%
ROIC (approx.)15.64%
Tax rate24.71%
Other income / net worth0.90%
Growth
Sales growth (latest year)22.67%
Profit growth (latest year)148.04%
Sales CAGR, 3 years4.09%
Sales CAGR, 5 years7.19%
Profit CAGR, 3 years4.00%
Profit CAGR, 5 years-2.01%
Sales growth QoQ11.85%
Profit growth QoQ31.69%
Sales growth YoY (latest quarter)29.10%
Profit growth YoY (latest quarter)125.49%
Per share
EPS (TTM)Rs 20.25
EPS (latest year)Rs 16.46
EPS (latest quarter)Rs 6.81
EPS, 3-year averageRs 8.70
EPS, 5-year averageRs 11.23
Book value per shareRs 98.18
Sales per shareRs 134.66
Cash flow per shareRs 30.07
Free cash flow per shareRs 10.37
Dividend per share (latest year)Rs 2.00
Dividend per share, 3-year averageRs 1.33
Dividend per share, 5-year averageRs 1.60
Dividends
Dividend payout12.15%
Dividend payout, 3-year average19.02%
Dividend payout, 5-year average16.74%
Efficiency
Asset turnover0.65x
Fixed asset turnover1.56x
Inventory turnover1.57x
Inventory days232 days
Debtor days115 days
Debtors turnover3.16x
Creditor days170 days
Cash conversion cycle263 days
Working capital days58 days
Leverage
Total debtRs 2,518 Cr
Cash and bankRs 114 Cr
Net debtRs 2,405 Cr
Debt to equity0.48x
Net debt / EBITDA1.15x
Interest coverage9.91x
Current ratio (filing 2026-03-31)1.33x
Quick ratio (filing 2026-03-31)0.68x
Trade payables (filing 2026-03-31)Rs 1,252 Cr
Owners' fund to total sources50.42%
Debt to assets23.96%
Cash flow
Cash from Operating Activity (latest year)Rs 1,624 Cr
Cash from Investing Activity (latest year)Rs -1,086 Cr
Cash from Financing Activity (latest year)Rs -525 Cr
Net Cash Flow (latest year)Rs 13 Cr
Free cash flow (latest year)Rs 560 Cr
FCFE (approx.: FCF + change in debt)Rs 315 Cr
Cash from ops / profit, 5 years1.58x
Sales to cash flow4.20x
Statement figures
Net sales (TTM)Rs 7,270 Cr
Net sales (latest year)Rs 6,813 Cr
Sales (latest quarter)Rs 2,026 Cr
Operating profit excl. other income (latest year)Rs 1,785 Cr
Operating profit (latest quarter)Rs 638 Cr
Other income (TTM)Rs 54 Cr
EBITDA (TTM)Rs 2,088 Cr
PBDT (TTM)Rs 1,926 Cr
Profit before tax (TTM)Rs 1,439 Cr
Tax (latest year)Rs 292 Cr
Net profit (TTM)Rs 1,093 Cr
Net profit (latest year)Rs 889 Cr
Net profit (latest quarter)Rs 368 Cr
Depreciation (TTM)Rs 487 Cr
Depreciation (latest quarter)Rs 124 Cr
Interest (TTM)Rs 161 Cr
Cost of goods sold (latest year)Rs 3,681 Cr
Total expenditure (latest year)Rs 5,028 Cr
Total income (latest year)Rs 6,860 Cr
Share capitalRs 108 Cr
ReservesRs 5,192 Cr
Shareholders' fundsRs 5,300 Cr
Total assetsRs 10,511 Cr
Net blockRs 4,371 Cr
Capital work in progressRs 773 Cr
InvestmentsRs 309 Cr
ReceivablesRs 2,155 Cr
InventoryRs 2,342 Cr
Other liabilitiesRs 2,693 Cr
Shares outstanding (crore)53.99
Ownership
Promoter holding27.47% (-0.13 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 98.0 is at the 85th percentile of its own 9.4-year range (median 34.9, low 19.1, high 202.7).
P/B 20.21 is at the 99th percentile (median 6.05).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodLAURUSLABSNifty 50Difference
1 week-2.1%-2.8% +0.7 pts
1 month+6.6%-6.8% +13.4 pts
3 months+28.6%-7.6% +36.3 pts
6 months+99.9%+0.4% +99.5 pts
1 year+121.3%-9.9% +131.3 pts
2 years+317.9%-13.6% +331.5 pts
3 years+401.8%+14.2% +387.6 pts
5 years+220.4%+27.9% +192.5 pts
184 mutual fund schemes hold about ₹8,252 Cr. Over three months 19 bought more and 125 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Mirae Asset Large & Midcap Fund3.79%1,735 -8%
Mirae Asset ELSS Tax Saver Fund4.31%1,138 -15%
Mirae Asset Midcap Fund4.03%842 -15%
UTI Nifty200 Momentum 30 Index Fund5.95%502 -3%
HSBC Small Cap Fund1.29%246 -8%
SBI Healthcare Opp Fund3.96%230 -15%
Axis Small Cap Fund0.70%222 -34%
Mirae Asset Aggressive Hybrid Fund1.98%190 -4%
Mirae Asset Healthcare Fund5.24%186 -12%
WOC Mid Cap Fund2.02%151 -31%
SBI Arbitrage Fund0.30%144 -57%
Edelweiss Mid Cap Fund0.63%125 -12%
Edelweiss Nifty Midcap150 Momentum 50 Index Fund6.32%116 +2%
Axis Multicap Fund0.90%98 -14%
ITI Small Cap Fund2.41%87 -13%
Tata Nifty Midcap 150 Momentum 50 Index Fund6.33%81 -6%
Aditya Birla SL Quant Fund3.56%72 -12%
Motilal Oswal Nifty Midcap 150 Index Fund1.74%72 -6%
Mahindra Manulife Multi Cap Fund0.93%71 -67%
Nippon India Nifty 500 Momentum 50 Index Fund5.64%70 -5%
UTI Multi Asset Allocation Fund0.95%67 -6%
Kotak Active Momentum Fund3.95%66 -38%
Mahindra Manulife Large & Mid Cap Fund2.12%62 -14%
Motilal Oswal Nifty 200 Momentum 30 Index Fund5.94%57 -3%
Axis India Manufacturing Fund0.92%53 -9%

Red flags

F-score 8 of 8
lookAuditor change Auditor change 2026-03-12: Laurus Labs Limited has informed the Exchange regarding Change in Auditors of the company.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2024-12-02PRATHIMA CHAVA-other200,000Rs 11.53 CrPledge Creation
2023-10-23G. SREELAKSHMIImmediate relativesell10,000Rs 0.38 CrMarket Sale
2022-03-17Venkata Jayasree Kumari TadikondaImmediate relativebuy788Rs 0.05 CrMarket Purchase
2022-03-16Venkata Jayasree Kumari TadikondaImmediate relativebuy3,992Rs 0.23 CrMarket Purchase
2022-03-14Venkata Jayasree Kumari TadikondaImmediate relativebuy2,906Rs 0.17 CrMarket Purchase
2022-02-22YAMINI TANGUTURIImmediate relativesell2,275Rs 0.12 CrMarket Sale
2022-02-15MADHURI MEDASANIImmediate relativebuy10,000Rs 0.54 CrMarket Purchase
2021-12-08Chandra kumariImmediate relativeother10,245Rs 0.52 CrPledge Creation
2021-09-17VIJAYA KUMARI SURYADEVARAImmediate relativesell12,000Rs 0.79 CrMarket Sale
2021-09-06SREELAKSHMI GOGIREDDYImmediate relativesell4,000Rs 0.26 CrMarket Sale
2021-08-31YALAMANCHI RAMAImmediate relativesell5,500Rs 0.36 CrMarket Sale
2021-08-11SRINIVASA RAO SURYADEVARAEmployees/Designated Employesell67,657Rs 4.76 CrMarket Sale
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹2,026 Cr +29.0% vs Jun 2025. Net profit ₹362 Cr +123.5%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-05-08Interim Dividend - Rs 1.20 Per Share
2025-10-31Interim Dividend - Re 0.80 Per Sh
2025-05-09Interim Dividend - Rs 0.80 Per Share
2024-11-06Interim Dividend - Rs 0.40 Per Share
2024-07-04Annual General Meeting
2024-05-08Interim Dividend - Re 0.40 Per Share
2023-11-02Interim Dividend - Re 0.40 Per Share
2023-07-07Annual General Meeting
2023-05-10Interim Dividend - Rs 1.20 Per Share
2022-11-03Interim Dividend - Rs 0.80 Per Share
2022-06-22Annual General Meeting
2022-05-10Interim Dividend - Rs 1.20 Per Share
2021-11-17 Interim Dividend - Rs 0.80 Per Share
2021-07-07 Annual General Meeting
2021-05-11 Interim Dividend - Re 0.80 Per Share
2021-02-08 Interim Dividend - Rs 0.40 Per Share
2020-11-10 Interim Dividend - Rs 0.80 Per Share
2020-09-29 Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 2/- Per Share0.2000
2020-07-01 Annual General Meeting/Dividend - Re 1 Per Share
2020-03-23 Interim Dividend - Rs 1.50 Per Share
2019-07-03 Annual General Meeting/ Dividend - Rs 1.50 Per Share
2018-06-28 Annual General Meeting / Dividend- Rs 1.50 Per Share
2017-07-06 Annual General Meeting/Dividend - Rs 1.50/- Per Share
DateTypeWhat it says
2026-09-18Investor PresentationInvestor Presentation
2026-09-15Concall / analyst meetSchedule of meet
2026-09-10Concall / analyst meetSchedule of meet
2026-08-31Concall / analyst meetSchedule of meet
2026-08-12Concall / analyst meetSchedule of meet
2026-08-10General UpdatesIntimation of ESG Score given by NSE Sustainability Ratings and Analytics Limited
2026-07-30Concall / analyst meetTranscript
2026-07-27General UpdatesAllotment of ESOP
2026-07-25General UpdatesUpdate On Composite Scheme of Arrangement
2026-07-24Concall / analyst meetLink of Recording
2026-07-24Press ReleaseA press release dated July 24, 2026, titled "Press Release for Q1 FY27".
2026-07-24Concall / analyst meetPresentation
2026-07-24Director changeChange in Director(s) of the company.
2026-07-24Board meeting outcomeLaurus Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-09Concall / analyst meetSchedule of meet
2026-07-06General UpdatesCompletion of tenure of Independent Director
2026-07-03Credit RatingCredit Rating
2026-07-02General UpdatesAppointment of Independent Directors at the 21st Annual General Meeting of the Company
2026-07-02Shareholder meetingProceedings of Annual General Meeting held on July 02, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with v...
2026-06-08Concall / analyst meetSchedule of meet
2026-06-08General UpdatesLetter To Shareholders Regarding Annual Report
2026-06-08UpdatesBusiness Responsibility and Sustainability Reporting (BRSR).
2026-06-08Shareholder meetingNotice of Annual General Meeting to be held on July 02, 2026
2026-06-05Disclosure under SEBI TakeovLaurus Labs Limited has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) and 31 (5) of the Securities and Exchange Board of India...
2026-06-04UpdatesAllotment of ESOP.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.73
Max pain (expiry 2026-10-27)1,960
Largest call open interest at2,000
Largest put open interest at1,800
Implied volatility, at the money32.2%
Underlying at snapshot1,984.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-308,469
2026-09-2939,100
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Close to Close price movement greater than 100perc in previous 365 daysClose to Close price movement greater than 75perc in previous 6 monthsHigh low price variation greater than 100perc in previous 6 monthsScrip PE is greater than 50 (4 trailing quarters)

Quick answers

What is the market cap of Laurus Labs Ltd?

Laurus Labs Ltd (LAURUSLABS) has a market capitalisation of Rs 1,06,928 Cr. at the 2026-10-01 close.

What is the P/E ratio of Laurus Labs Ltd?

Laurus Labs Ltd trades at a P/E of 97.8 on trailing twelve-month profit, at the 2026-10-01 close.

What were Laurus Labs Ltd's latest quarterly results?

In the Jun 2026 quarter, Laurus Labs Ltd sales was Rs 2,026 Cr (+29.0% vs Jun 2025) and net profit was Rs 362 Cr.

What is the 52-week high and low of Laurus Labs Ltd?

The 52-week high is Rs 2,055.30 and the 52-week low is Rs 827.25.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03